Global computational biology market

Global Computational Biology Market Size, Share, Growth Analysis, By Application(Cellular, Biological Simulation), By End-User(Academics, Commercial), By Service(In-House and Contract) - Industry Forecast 2024-2031


Report ID: SQMIG35A2634 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 90 | Figures: 76

Global Computational Biology Market Competitive Landscape

Given the presence of multiple significant competitors, the computational biology market is predicted to become extremely competitive in the near future. Mid-size to smaller businesses are expanding their market presence by releasing new products with lower prices as a result of rising technical breakthroughs and product innovations. Major companies in the market are concentrated on developing new items to extend their product portfolio as well as on implementing collaborative methods to increase their market share. For instance, Genedata, AG released Genedata Imagence 2.0, the most recent iteration of its corporate software for high-content screening (HCS) image analysis, in May 2020.

Top Players in the Global Computational Biology Market

  • Certara
  • Insilico Biotechnology AG 
  • Strand Life Sciences
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Qiagen N.V.
  • PerkinElmer Inc.
  • Agilent Technologies, Inc.
  • Dassault Systemes
  • Genedata AG
  • Biomax Informatics AG
  • Compugen Ltd.
  • Rhenovia Pharma SAS
  • Chemical Computing Group Inc.
  • Simulation Plus, Inc.
  • InSilico Medicine, Inc.
  • Geneious Biologics
  • Novo Informatics Pvt. Ltd.
  • Precision for Medicine, Inc.
  • Schrödinger, Inc.

Computational Biology Market Recent Development

  • In April 2022, Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced that the company granted non-statutory stock options to purchase an aggregate of 101,715 shares of the company's common stock to 30 newly hired employees, including six freshly hired employees based in India and one newly hired employee based in Japan.
  • In May 2022, Genedata, the leading supplier of enterprise software solutions for biopharmaceutical Research and Development, announced that Ajinomoto, a multinational provider to the biopharmaceutical industry of cell culture media and development and manufacturing services (CDMO), has implemented Genedata Bioprocess® to digitalize and automate their R&D and manufacturing operations in Japan and Korea.
  • In May 2021 Certara, Inc., the world leader in biosimulation, has released new versions of its Quantitative Systems Pharmacology (QSP) Simulators for Immunogenicity (IG) and Immuno-oncology (IO) to aid in the development of biologics and cancer treatments.
  • In April 2021, Peptilogics, a biotechnology platform company leveraging computational design to discover novel peptide therapeutics, announced the successful completion of Phase 1 clinical trial for its lead compound PLG0206, a potent, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections (PJI).
  • In March 2021, Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, has published a review article titled "Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis," which looks at the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy.
  • In January 2021, AsclepiX Therapeutics Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and oncologic diseases, announced that the first patient has been dosed in the Phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with Diabetic Macular Edema (DME).
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Computational Biology Market size was valued at USD 6880 million in 2019 and is poised to grow from USD 4527.82 million in 2023 to USD 18083.66 million by 2031, growing at a CAGR of 18.89% in the forecast period (2024-2031).

Given the presence of multiple significant competitors, the computational biology market is predicted to become extremely competitive in the near future. Mid-size to smaller businesses are expanding their market presence by releasing new products with lower prices as a result of rising technical breakthroughs and product innovations. Major companies in the market are concentrated on developing new items to extend their product portfolio as well as on implementing collaborative methods to increase their market share. For instance, Genedata, AG released Genedata Imagence 2.0, the most recent iteration of its corporate software for high-content screening (HCS) image analysis, in May 2020. 'Certara', 'Insilico Biotechnology AG ', 'Strand Life Sciences', 'Thermo Fisher Scientific Inc.', 'Illumina, Inc.', 'Qiagen N.V.', 'PerkinElmer Inc.', 'Agilent Technologies, Inc.', 'Dassault Systemes', 'Genedata AG', 'Biomax Informatics AG', 'Compugen Ltd.', 'Rhenovia Pharma SAS', 'Chemical Computing Group Inc.', 'Simulation Plus, Inc.', 'InSilico Medicine, Inc.', 'Geneious Biologics', 'Novo Informatics Pvt. Ltd.', 'Precision for Medicine, Inc.', 'Schrödinger, Inc.'

Demand for computational biology is anticipated to increase as better computational tools for genome sequencing become more widely available. Computer programmes assist in creating PCR primers, display restriction enzyme cut sites on any piece of DNA, convert DNA sequences into amino acid sequences, and perform a variety of other tasks. Scientists may now easily get a wealth of information about the structure of genes, their encoded message, and many other topics because to the expanding availability of databases and sequence analysis software. By locating functionally significant protein sequences in these sizable datasets, computational methods improve the efficiency of the drug creation process. For instance, the protein targets found in microbial genomes can be used to destroy diseases or create useful enzymes that can be further commercialised. The computer-based prediction of protein function is the most efficient way for selecting valuable proteins from large genetic databases.

The growing number of clinical studies in the area of pharmacogenomics is the main factor driving the global market for computational biology. This has improved knowledge of the patient population's varied biological make-up, biological pathways, and the genomes that underlie them. Computational biology solutions are in high demand since they shorten the duration of various scientific investigations and the search for new drugs. In addition, a rising need for computational biology in the fields of epigenomics, proteomics, and meta-genomics to understand protein structures and interactions is also boosting the market growth. Additionally, significant technological developments in disease modeling and drug development, as well as increased investments in research and development (R&D) activities by both private and public institutions, are also anticipated.

North America contributes to the largest market share and It is anticipated that will significantly impact the worldwide industry. During the projected period, strong government support for genetically based research, an increase in public-private partnerships, and industry-academia cooperation are anticipated to be favourable factors for regional growth.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global computational biology market

Product ID: SQMIG35A2634

$5,300
BUY NOW GET FREE SAMPLE